Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Advanced Melanoma and Urological Cancers
NCT02836795Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in melanoma and urological cancer (UC), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 1.5 years. Started Apr 2016; status: completed.
02
Drugs
toripalimab
03
Conditions
melanomaurological cancer (UC)
Beyond the preview
Go deeper on NCT02836795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836795.